| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e232689f4a1fc9ec99d4344c059b061b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d055f2f083f2464672191cbfc70a81ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0d2ae31c3e078e4db0b58abd07ac590
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df6a47e123313c42cc4af35c4862daf6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001194 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-711 |
| filingDate |
2006-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_361ea09973ed7d86bfc561d2ed41cf8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c831509c7f88c9775a05b9b5ed559d08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3cef5bd1a8ca3d6d9499500b1364842
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf88949d9ed55897dec9b9262343462b |
| publicationDate |
2010-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010047260-A1 |
| titleOfInvention |
Methods and Compositions Relating To a Vaccine Against Prostate Cancer |
| abstract |
An object of the invention is to provide methods and compositions relating to a vaccine against prostate cancer which includes a non-human-primate PSA for administration to humans to provide an immune response against human PSA. More generally, an object of the invention is to provide methods and compositions relating to using a non-human primate xenogeneic antigen (e.g. protein) in a human, wherein, with respect to the non-human primate xenogeneic antigen that is used, there are relatively few interspecies differences between the non-human primate xenogeneic antigen and the human self antigen in order to induce an optimal immune response in the human to its native self antigen. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9240178-B1 |
| priorityDate |
2005-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |